These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 8341767

  • 41. A pharmacodynamic model to predict the time dependent adaptation of dopaminergic activity during constant concentrations of haloperidol.
    Cheng YF, Paalzow LK.
    J Pharm Pharmacol; 1990 Aug; 42(8):566-71. PubMed ID: 1981585
    [Abstract] [Full Text] [Related]

  • 42. Chronic haloperidol or fluphenazine: effects on dopamine metabolism in brain, cerebrospinal fluid and plasma of Cercopithecus aethiops (vervet monkey).
    Bacopoulos NG, Redmond DE, Baulu J, Roth RH.
    J Pharmacol Exp Ther; 1980 Jan; 212(1):1-5. PubMed ID: 6766186
    [Abstract] [Full Text] [Related]

  • 43. [Relationship of the homovanillic acid content in the rat brain after the administration of a neuroleptic and the degree of dopamine receptor sensitivity to an agonist].
    Zharkovskiĭ AM, Allikmets LKh, Otter MIa.
    Biull Eksp Biol Med; 1979 Jun; 87(6):559-60. PubMed ID: 572714
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia.
    Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter S, Knott P, Davis KL.
    Psychiatry Res; 1993 Feb; 46(2):151-63. PubMed ID: 8483974
    [Abstract] [Full Text] [Related]

  • 46. Dopamine turnover in the intact rabbit brain: effect of pentobarbital or haloperidol.
    Barkai AI.
    J Pharmacol Exp Ther; 1978 Apr; 205(1):133-40. PubMed ID: 633078
    [Abstract] [Full Text] [Related]

  • 47. Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin.
    Maas JW, Contreras SA, Seleshi E, Bowden CL.
    Arch Gen Psychiatry; 1988 Jun; 45(6):553-9. PubMed ID: 3377641
    [Abstract] [Full Text] [Related]

  • 48. Lithium prevents adaptation of brain dopamine systems to haloperidol in schizophrenic patients.
    Sternberg DE, Bowers MB, Heninger GR, Charney DS.
    Psychiatry Res; 1983 Oct; 10(2):79-86. PubMed ID: 6581492
    [Abstract] [Full Text] [Related]

  • 49. Serum homovanillic acid levels in schizophrenic patients and normal control subjects.
    Steinberg JL, Garver DL, Moeller FG, Raese JD, Orsulak PJ.
    Psychiatry Res; 1993 Aug; 48(2):93-106. PubMed ID: 8416025
    [Abstract] [Full Text] [Related]

  • 50. Chronic haloperidol treatment with low doses may enhance the increase of homovanillic acid in rat brain.
    Chang WH, Jaw SS, Tsay L.
    Eur J Pharmacol; 1989 Mar 14; 162(1):151-6. PubMed ID: 2721561
    [Abstract] [Full Text] [Related]

  • 51. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
    Haleem DJ, Batool F, Khan NH, Kamil N, Ali O, Saify ZS, Haleem MA.
    Med Sci Monit; 2002 Sep 14; 8(9):BR354-61. PubMed ID: 12218936
    [Abstract] [Full Text] [Related]

  • 52. Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.
    Pickar D, Breier A, Kelsoe J.
    Ann N Y Acad Sci; 1988 Sep 14; 537():339-46. PubMed ID: 2904783
    [Abstract] [Full Text] [Related]

  • 53. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls.
    Davidson M, Davis KL.
    Arch Gen Psychiatry; 1988 Jun 14; 45(6):561-3. PubMed ID: 3377642
    [Abstract] [Full Text] [Related]

  • 54. Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
    Csernansky JG, Newcomer JW, Jackson K, Lombrozo L, Faull KF, Zipursky R, Pfefferbaum A, Faustman WO.
    Psychopharmacology (Berl); 1994 Nov 14; 116(3):291-6. PubMed ID: 7534423
    [Abstract] [Full Text] [Related]

  • 55. Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
    Davidson M, Kendler KS, Davis BM, Horvath TB, Mohs RC, Davis KL.
    Psychiatry Res; 1985 Oct 14; 16(2):95-9. PubMed ID: 3865258
    [Abstract] [Full Text] [Related]

  • 56. Effects of subchronic haloperidol and sulpiride on regional brain dopamine metabolism in the rat.
    Lindefors N, Sharp T, Ungerstedt U.
    Eur J Pharmacol; 1986 Oct 07; 129(3):401-4. PubMed ID: 3780852
    [Abstract] [Full Text] [Related]

  • 57. Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics.
    Harris PQ, Brown SJ, Friedman MJ, Bacopoulos NG.
    Biol Psychiatry; 1984 Jun 07; 19(6):849-60. PubMed ID: 6146355
    [Abstract] [Full Text] [Related]

  • 58. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.
    Den Boer JA, Ravelli DP, Huisman J, Ohrvik J, Verhoeven WM, Westenberg HG.
    Psychopharmacology (Berl); 1990 Jun 07; 102(1):76-84. PubMed ID: 1975448
    [Abstract] [Full Text] [Related]

  • 59. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.
    Nomura Y, Komori T, Okuda S, Segawa T.
    Arch Int Pharmacodyn Ther; 1979 Jan 07; 237(1):25-30. PubMed ID: 485682
    [Abstract] [Full Text] [Related]

  • 60. Elevation of plasma homovanillic acid level can be detected within four hours after initiation of haloperidol treatment.
    Davila R, Zumarraga M, Perea K, Andia I, Friedhoff AJ.
    Arch Gen Psychiatry; 1987 Sep 07; 44(9):837-8. PubMed ID: 3632258
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.